Amarin a 'Strong buy' ahead of federal circuit ruling, says Roth Capital
May 04, 2020 at 11:07 AM EDT
Roth Capital analyst Yasmeen Rahimi sees COVID-19 disruptions as only a "minor distraction" from Amarin's continued commercial rollout of Vascepa.
